Abstract
Numerous publications have confirmed Dale’s initial observation that the effect of ergotoxine on blood pressure in normotensive or spinal animals is universally pressor (Dale, 1906; Barger and Dale, 1907). The substance is considerably more potent than might appear from the experiments of early workers, who consistently used doses which must be regarded as toxic. A marked pressor effect can be obtained in the anesthetised cat with an intravenous dose as low as 50 μg/kg (Lands et al., 1950). Blood pressure increases in response to each of the components of ergotoxine (23, 24, 25, 26)* (Rothlin, 1946; Schlientz et al., 1968).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abel, F.L., Pierce, J.H., Guntheroth, W.G.: Baroreceptor influence on postural changes in blood pressure and carotid blood flow. Amer. J. Physiol. 205, 360–364 (1963)
Abramson, D.I., Lichtman, S.S.: Influence of ergotamine tartrate upon peripheral blood flow in subjects with liver disease. Proc. Soc. exp. Biol. (N.Y.) 37, 262–267 (1937)
Abreu, B.E., Liddle, G.W., Handley, C.A., Elliott, H.W.: Preliminary observations on the influence of ergotamine and dihydroergotamine on cerebral blood flow in the dog. Fed. Proc. 6, 304 (1947)
Abreu, B.E., Liddle, G.W., Burks, A.L., Simon, A., Sutherland, V., Gordan, G.S.: Effects of amphetamine, dihydroergotamine and methadon on human cerebral blood flow and oxygen uptake. Fed. Proc. 7, 201 (1948)
Achari, G., Ahmad, M.: Antiarrhythmic activity of cyproheptadine and methysergide. Indian Heart J. 18, 4–16 (1966)
Aellig, W.H.: Periphere Kreislaufwirkungen von Ergotamin, Dihydroergotamin und 1-Methylergotamin an der innervierten, perfundierten Hinterextremitat des Hundes. Helv. physiol. Pharmacol. Acta 25, 374–396 (1967)
Aellig, W.H.: Venoconstrictor effect of dihydroergotamine in superficial hand veins. Europ. J. clin. Pharmacol. 7, 137–139 (1974)
Aellig, W.H.: Venentonisierende Wirkung von Ergotalkaloiden, untersucht an oberflachlichen Handvenen in situ. Cardiology 61 (Suppl.), 302–308 (1976a)
Aellig, W.H.: Influence of ergot compounds on compliance of superficial hand veins in man. Postgrad. med. J. 52 (Suppl. 1), 21–23 (1976b)
Aellig, W.H.: Clinical pharmacological experiments with pizotifen (Sanomigran®) on superficial hand veins in man. In: Current Concepts in Migraine Therapy. Green, R. (ed.), pp. 53–62. New York: Raven Press 1978
Aellig, W.H., Berde, B.: Studies of the effect of natural and synthetic polypeptide type ergot compounds on a peripheral vascular bed. Brit. J. Pharmacol. 36, 561–570 (1969)
Aellig, W.H., Nuesch, E.: Comparative pharmacokinetic investigations with tritium-labelled ergot alkaloids after oral and intravenous administration in man. Int. J. clin. Pharmac. 15, 106–112 (1977)
Ahlquist, R.P.: A study of the adrenergic receptors. Amer. J. Physiol. 153, 586–599 (1948)
Alexander, R.S.: The participation of the venomotor system in pressor reflexes. Circulat. Res. 2, 405–409 (1954)
Allen, C.R., Stutzman, J.W., Meek, W.J.: The production of ventricular tachycardia by adrenaline in cyclopropane anaesthesia. Anesthesiology 1, 158–166 (1940)
Allen, C.R., Stutzman, J.W., Slocum, H.C., Orth, O.S.: Protection from cyclopropane-epinephrine tachycardia by various drugs. Anesthesiology 2, 503–514 (1941)
Altura, B.M.: Chemical and humoral regulation of blood flow through the precapillary sphincter. Microvasc. Res. 3, 361–384 (1971)
Amsler, C.: Über inverse Adrenalinwirkung. Arch. Physiol. 185, 86–92 (1920)
Andrus, E.C., Martin, L.E.: The action of the sympathetic upon the excitatory process in the mammalian heart. J. exp. Med. 14, 1017–1024 (1927)
Anthony, M.: Patterns of plasma free fatty acid and prostaglandin E1 changes in migraine and stress. Sixth Migraine Symposium. London, England, Sept., p. 4, 1974
Anthony, M., Hinterberger, H., Lance, J.W.: Plasma serotonin in migraine and stress. Arch. Neurol. (Chic.) 16, 544–552 (1967)
Antonaccio, M.J., Coté, D.: Centrally mediated antihypertensive and bradycardic effects of methysergide in spontaneously hypertensive rats. Europ. J. Pharmacol. 36, 451–454 (1976)
Antonaccio, M.J., Kelly, E., Halley, J.: Centrally mediated hypotension and bradycardia by methysergide in anaesthetised dogs. Europ. J. Pharmacol. 33, 107–117 (1975)
Antonaccio, M.J., Taylor, D.G.: Reduction in blood pressure, sympathetic nerve discharge and centrally evoked pressor responses by methysergide in anaesthetized cats. Europ. J. Pharmacol. 42, 331–338 (1977)
Arcari, G., Dorigotti, L., Fregnan, G.B., Glässer, A.H.: Vasodilating and alpha-receptor blocking activity of a new ergoline derivative. Brit. J. Pharmacol. 34, 700P (1968)
Arcari, G., Bernardi, L., Bosisio, G., Coda, S., Fregnan, G.B., Glässer, A.H.: 10-Methoxyergoline derivatives as α-adrenergic blocking agents. Experientia (Basel) 28, 819–820 (1972)
Ariëns, E.J., Simonis, A.M.: Receptors and receptor mechanisms, in: Beta-Adrenoceptor Blocking Agents. Saxena, P.R., Forsyth, R.P. (eds.). Amsterdam: North Holland Publishing Co. 1976
Aschke, J., Trieb, G., Nusser, E.: Die dynamische Labilitat der Blutdruckregulation und ihre therapeutische Beeinflussung. Munch. med. Wschr. 114, 97–102 (1972)
Assali, N.S., Dasgupta, K., Kolin, A.: Measurement of uterine blood flow and uterine metabolism. VI. Effects of oxytocic, vasopressor and vasodepressor drugs on the blood flow to the postpartum uterus in unanaesthetised sheep. Amer. J. Obstet. Gynec. 78, 313–321 (1959)
Athanasiou, D.J.: Die pharmakologische Beeinflussung des Valsalva-Versuches bei fortlaufender Blutdruckregistrierung. Z. klin. Med. 145, 340–345 (1949)
Axelrod, J., Brady, R.O., Witkop, B., Evarts, E.V.: Metabolism of lysergic acid diethylamide. Nature (Lond.) 178, 143–144 (1956)
Bachmann, K., Graf, N., Heynen, H.-P.: Regulationsstorungen des Kreislaufs und ihre Behandlung mit Dihydroergotamin. Fortschr. Med. 86, 535–537 (1968)
Bacq, Z.M., Brouha, L., Heymans, C.: Recherche sur la physiologie et la pharmacologic du système nerveux autonome. Arch. int. Pharmacodyn. 48, 429–456 (1934)
Bacq, Z.M., Bremer, F., Brouha, L., Heymans, C.: Reflexes vasomoteurs chez le chat sympathectomisé non anaesthésié. Arch. int. Pharmacodyn. 62, 460–473 (1939)
Baldy-Moulinier, M.: Influence de l’hydergine sur les variations physiologiques et pathologiques de debit sanguin du cortex cerebral. Path. et Biol. 16, 759–764 (1968)
Bálint, G.: Effect on blood pressure of drug combinations containing phenothiazine derivatives and hydergine. Acta physiol. Acad. Sci. hung. 26, 361–368 (1965)
Baráth, E.: Untersuchungen über die Ergotaminwirkung bei Menschen, mit besonderer Rücksicht auf seine klinischen Anwendungsmöglichkeiten bei inneren Erkrankungen. Z. klin. Med. 104, 712–718 (1926)
Barbey, K., Brecht, K.: Venentonus, Venenkapazität und ihre Messung. Med. Welt 1, 727–732 (1965)
Barcroft, H., Konzett, H., Swan, H.J.C.: Observations on the action of the hydrogenated alkaloids of the ergotoxine group on the circulation in man. J. Physiol. (Lond.) 112, 273–291 (1951)
Barger, G., Dale, H.H.: Ergotoxine and some other constituents of ergot. Biochem. J. 2, 240–299 (1907)
Barry, D.T.: Some features of the pharmacological actions of yohimbine and ergotamine. Arch. int. Pharmacodyn. 55, 385–401 (1937)
Baumann, D.P., Jerram, D.C., Seager, L.D.: Mechanism of bradycardia induced by hydrogenated ergot alkaloids. Fed. Proc. 13, 334–335 (1954)
Becattini, U., Cangi, G., Termini, F.: Azione dell’Hydergina sul flusso sanguigno degli arti inferiori. Settim. Med. 52, 703–707 (1964)
Bell, C., Conway, E.L., Lang, W.J.: Ergometrine and apomorphine as selective antagonists of dopamine in the canine renal vasculature. Brit. J. Pharmacol. 52, 591–595 (1974)
Bell, C., Conway, E.L., Lang, W.J., Padanyi, R.: Vascular dopamine receptors in the canine hindlimb. Brit. J. Pharmacol. 55, 167–172 (1975)
Benfey, B.G., Kunos, G., Nickerson, M.: Dissociation of cardiac inotropic and adenylate cyclase activating adrenoceptors. Brit. J. Pharmacol. 51, 253–257 (1974)
Bennett, W.D., Dhuner, K.-G., Orth, O.S.: A comparison of the effectiveness of dihydroergotamine (DHE-45) and dihydroergocornine (DHO-180) in the prevention of cardiac irregularities during cyclopropane anesthesia. J. Pharmacol. exp. Ther. 95, 287–292 (1949)
Bennett, A., Magnaes, B., Sandler, M., Sjaastad, O.: Prostaglandins and headache. Sixth Migraine Symposium, London, Sept., p12, 1974
Bergenwald, L., Ecklund, B., Kaijser, L., Klingenström, P.: Haemodynamic effects of dihydroergotamine during spinal anaesthesia in man. Acta anaesthesiol. scand. 16, 235–239 (1972)
Bergh, R. van den: L’influence de quelques medicaments usuels sur la vasomotricity carotidienne. Acta neurol. belg. 56, 459–475 (1956)
Berne, R.M.: Effect of epinephrine and norepinephrine on coronary circulation. Circulat. Res. 6, 644–655 (1958)
Bernsmeier, A.: Die chemische Blockierung des adrenergischen Systems am Menschen. Acta neuroveg., Suppl. 5. Wien: Springer 1954
Bevegård, S., Castenfors, J., Lindblad, L.E.: Haemodynamic effects of dihydroergotamine in patients with postural hypotension. Acta med. scand. 196, 473–477 (1974)
Bianco, P.L. del, Fanciullacci, M., Franchi, G., Sicuteri, F.: Human 5-hydroxytryptamine venomotor receptors. Pharmacol. Res. Commun. 7, 395–408 (1975)
Biber, B., Fara, J., Lundgren, O.: A pharmacological study of intestinal vasodilator mechanisms in the cat. Acta physiol. scand. 90, 673–683 (1974)
Bidart, Y., Maury, M.: Effets de la dihydroergotamine sur l’adaption vaso-motrice à l’orthostatisme chez les paraplégiques. Ann. Méd. phys. 17, 235–242 (1974)
Bircher, R., Cerletti, A.: Pharmakodynamische Grundlagen der Therapie von Kreislaufstörungen mit den dihydroalkaloiden des Mutterkorns. Helv. med. Acta, Suppl. XXII, 13–26 (1949)
Blake, W.D.: Some effects of dihydrogenated ergot alkaloids on renal haemodynamics, water and electrolyte excretion in the dog. Amer. J. Physiol. 173, 337–344 (1953)
Bluntschli, H.J.: Über die Wirkung eines Ergot-Derivates (Dihydroergocornin) auf Blutdruck, Respiration und Elektrokardiogramm der Katze nach Querschnittsdurchtrennung des Rückenmarks im Bereich der Thoracal-Segmente. Helv. physiol. pharmacol. Acta 6, C50–C51 (1948)
Bluntschli, H.J., Goetz, R.H.: The effect of ergot derivatives on the circulation in man with special reference to two new hydrogenated compounds (dihydroergotamine and dihydroergocornine). Amer. Heart J. 35, 873–894 (1948)
Bluntschli, H.J., Eyband, M., Staub, H.: Über Blutdruckwirkungen von Angiotonin und hydrierten Ergotoxinderivaten (Dihydroergocornin, Hydergin) an der Katze. Helv. physiol. Pharmacol. Acta 7, 406–409 (1949)
Bocci, U., Bignotti, N., Luzi, T.: L’azione normotensiva della diidroergotamina nelle alterazioni pressorie da psicofarmaci. Riv. sper. Freniat. 94, No. 2 (1970)
Boer, J. de, Van Dongen, K.: Experiments with dihydroergotamine. Arch. int. Pharmacodyn. 77, 434–441 (1948)
Boismare, F., Derrey, D., Adisio, M., Brocheriou, J.: Hypotension posturale provoquée par les neuroleptiques: étude rhéographique de l’effet de correcteurs (néosynéphrine, dihydroergotamine et chlorhydrate d’heptaminol). Thérapie 29, 435–446 (1974)
Boismare, F., Hacpille, L., Belliard, J.P.: Etude rhéographique des effets de la dihydroergotamine sur l’hemodynamique encéphalique et périphérique chez les sujets sains. Thérapie 30, 149–156 (1975a)
Boismare, F., Hacpille, L., Belliard, J., Colin, C.: Effects of dihydroergotamine on postural hypotension induced by levomepromazine. J. Pharmacol. (Paris) 6, 391–400 (1975b)
Bojanovsky, J., Toelle, R.: Dihydroergotamin gegen die Kreislaufwirkungen der Thymoleptika. Dtsch. med. Wschr. 99, 1064–1069 (1974)
Bouckaert, J.J., Grimson, K.S., Heymans, C., Samaan, A.: Sur la méchanisme de l’influence de l’hypoxémie sur la respiration et la circulation. Arch. int. Pharmacodyn. 65, 63–100 (1941)
Broghammer, H., Takagi, K., Schaefer, H.: Die Wirkung von Lysergsäure-Diäthylamid (LSD) und Urethan auf die Tätigkeit eines sympathischen Ganglions. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 230, 358–366 (1957)
Brooke, O.G., Robinson, B.F.: Effect of ergotamine and ergometrine on forearm venous compliance in man. Brit. med. J. 1, 139–142 (1970)
Buckley, G.A., Jordan, C.C.: Temperature modulation of α-and β-adrenoceptors in the isolated frog heart. Brit. J. Pharmacol. 38, 394–398 (1970)
Buñag, R.D., Walaszek, E.J.: Blockade of depressor responses to serotonin and tryptamine by lysergic acid derivatives in the chicken. Arch. int. Pharmacodyn. 135, 142–151 (1962)
Buttermann, G., Hör, G., Pabst, H.W.: Progress in prevention of postoperative thromboembolism — a controlled clinical trial using radio-fibrinogen-uptake-test and lung-perfusion-scan. 4th Mediterranean congress on thromboembolism. Athens, Greece, May 2–6, Abstr. 25 (1976)
Buttermann, G., Theisinger, W., Oechsler, H., Hör, G.: Untersuchungen über die postoperative Thromboembolieprophylaxe nach einem neuen medikamentösen Behandlungsprinzip. Dtsch. med. Wschr. 41, 2065–2069 (1975)
Cairoli, V., Reilly, J., Ito, R., Roberts, J.: The relation of the digitalis-induced arrhythmia to catecholamine release. Fed. Proc. 21, 127 (1962)
Capps, R.T., Suckle, H.M., Orth, O.S.: A comparison of protective action of the dihydrogenated ergot alkaloids to cyclopropane-epinephrine ventricular tachycardia. Amer. J. Physiol. 163, 702–703 (1950)
Carlson, L.A., Ekelund, L.G., Oro, L.: Clinical and metabolic effects of different doses of prostaglandin E in man. Acta med. scand. 183, 423–430 (1968)
Carpi, A., Virno, M.: The action of ergotamine on the intracranial venous pressure and on the cerebral venous outflow of the dog. Brit. J. Pharmacol. 12, 232–239 (1957)
Carroll, P.R., Ebeling, P.W., Glover, W.E.: The responses of the human temporal and rabbit ear artery to 5-hydroxytryptamine and some of its antagonists. Aust. J. exp. Biol. med. Sci. 52, 813–823 (1974)
Castenfors, J., Lindblad, L.E., Mortasawi, A.: Effect of dihydroergotamine on peripheral circulation during epidural anaesthesia in man. Acta anaesth. scand. 19, 79–84 (1975)
Cerletti, A.: Lysergic acid diethylamide (LSD) and related compounds. Neuropharmacology: Trans. 2nd Conf. Princeton, 1955. Abramson, H.A. (ed.), pp. 9–84. Josiah Macy Jr. Foundation 1956
Cerletti, A.: Gynaecologia (Basel) 128, 452–453 (1949)
Cerletti, A., Berde, B.: New approaches in the development of compounds from ergot with potential therapeutic use in migraine. In: Background to migraine. 2nd migraine symposium. Smith, R. (ed.), pp. 53–65, London 1969
Cerletti, A., Doepfner, W.: Comparative study on the serotonin antagonism of amide derivatives of lysergic acid and of ergot alkaloids. J. Pharmacol. exp. Ther. 122, 124–136 (1958)
Cerletti, A., Rothlin, E.: Role of 5-hydroxytryptamine in mental diseases and its antagonism to lysergic acid derivatives. Nature (Lond.) 176, 785–786 (1955)
Cervoni, P., Bertino, J.R., Geiger, L.E.: Medullary vagal effects of d-lysergic acid diethylamide in the decerebrate cat. Nature (Lond.) 199, 700–701 (1963)
Chalmers, J.P.: Brain amines and models of experimental hypertension. Circulat. Res. 36, 469–480 (1975)
Chapuis, J.P.: Migraines, céphalées et sympathicolyptiques. Schweiz. med. Wschr. 78, 1125–1126 (1948)
Chong, G.C., Phillis, J.W.: Pharmacological studies on the heart of Tapes Watlingi: A mollusc of the family veneridae. Brit. J. Pharmacol. 25, 481–496 (1965)
Chu, D., Hool-Zulauf, B.: Studies on the reserpine-induced potentiation of the peripheral vascular effect of DHE in cats. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 287, R22 (1975)
Chu, D., Stürmer, E.: Studies on the mechanism of dihydroergotamine (DHE) on the vascular bed of cat skeletal muscle. Brit. J. Pharmacol. 48, 331P–332P (1973)
Chu, D., Owen, D.A.A., Stürmer, E.: Effects of ergotamine and dihydroergotamine on the resistance and capacitance vessels of skin and skeletal muscle in the cat. Postgrad. med. J. 52 (Suppl. 1), 32–36 (1976)
Clark, B.J.: Dopamine receptor stimulants in hypertension. Acta med. scand. Suppl. 606, 95–99 (1977)
Clark, B.J., Scholtysik, G., Flückiger, E.: Cardiovascular actions of bromocriptine. In: The dopamine agonist, Bromocriptine. Hokfelt, B., Nillius, S.J. (eds.). Acta endocr. (Kbh.) Suppl. (1978) in press
Cobbold, A., Folkow, B., Kjellmer, I., Mellander, S.: Nervous and local chemical control of pre-capillary sphincters in skeletal muscle as measured by changes in filtration coefficient. Acta physiol. scand. 57, 180–192 (1963)
Corrodi, H., Fuxe, K., Hokfelt, T., Lidbrink, P., Ungerstedt, U.: Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons. J. Pharm. Pharmacol. 25, 409–412 (1973)
Corsi, V., Dohrn, P.: Ergotamina e attività reflessogena senocarotidea (Nota I: Attività sinusale alia compressione nei normotesi). Boll. Soc. med.-chir. Catania 14, 245–250 (1946)
Corsi, V.: Contributo di recerche cliniche ed elettrocardiografiche sull’ ipertensione da noradrenalina. G. Med. Tisiol. 1, 21 (1952)
Cotten, M. de V., Walton, R.P.: Dibenamine blockade as a method of distinguishing between inotropic actions of epinephrine and digitalis. Proc. Soc. exp. Biol. (N.Y.) 78, 810–815 (1951)
Cotten, M. de V., Moran, N.C., Stopp, P.E.: A comparison of the effectiveness of adrenergic blocking drugs in inhibiting the cardiac actions of sympathomimetic amines. J. Pharmacol. exp. Ther. 121, 183–190 (1957)
Craig, W.M.: Localised headache associated with lesion of meningeal vessels. J. Amer. med. Ass. 100, 816 (1933)
Crosley, A.P., Cummins, A.J., Barker, H.G., Clark, J.K.: The renal hemodynamic effects of dihydroergocornine (DHO-180) in man. J. Pharmacol. exp. Ther. 98, 138–143 (1950)
Curran, D.A., Hinterberger, H., Lance, J.W.: Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects. Brain 88, 997–1010 (1965)
Curran, D.A., Hinterberger, H., Lance, J.W.: Methysergide. Res. Clin. Stud. Headache 1, 77–122. Basel-New York: Karger 1967
Curzon, G., Theaker, P., Phillips, B.: Excretion of 5-hydroxyindolyl acetic acid (5HIAA) in migraine. J. Neurol. Neurosurg. Psychiat. 29, 85 (1966)
Dale, H.H.: On some physiological actions of ergot. J. Physiol. (Lond.) 34, 163–206 (1906)
Dale, H.H., Spiro, K.: Die wirksamen Alkaloide des Mutterkorns. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 95, 337–350 (1922)
Dalessio, D.J.: Recent experimental studies on headache. Neurology (Minneap.) 13, 7–10 (1963)
Dalessio, D.J., Camp, W.A., Goodell, H., Wolff, H.G.: Studies on headache. Arch. Neurol. (Chic.) 4, 235–240 (1961)
David, N.A., Kirchof, A.C.: Studies on d-lysergic acid and hydrobutylamide-(2) (methergine). Schweiz. med. Wschr. 77, 13–17 (1947)
Davis, M.E., Adair, F.L., Chen, K.K., Swanson, E.E.: The pharmacologic action of ergotocin, a new ergot principle. J. Pharmacol. exp. Ther. 54, 398–407 (1935)
Davis, W.G., McDonald, D.C., Mason, D.F.J.: The effects of pronethalol and propranolol on the coronary circulation of the dog. Brit. J. Pharmacol. 37, 338–356 (1969)
Delaunois, A.L., Martini, L.: Adrenolytic drugs and action of adrenaline and noradrenaline on carotid sinus wall and blood pressure. Arch. int. Pharmacodyn. 94, 430–438 (1953)
Delius, L., Hammerschmidt, D., Odenthal, F.: Klinisch-experimentelle Untersuchungen über die kreislaufdynamischen Wirkungen der dihydrierten Mutterkornalkaloide. Klin. Wschr. 27, 33–34 (1949)
Deutsch, E., Markoff, T.: Mitteilungen zur Nierenclearance. Klin. Med. 8, 105–115 (1953)
Dickerson, D.G.: The surgical relief of the headache in migraine. J. nerv. ment. Dis. 77, 42 (1933)
Doepfner, W., Cerletti, A.: Comparison of lysergic acid derivatives and antihistamines as inhibitors of the edema provoked in the rat’s paw by serotonin. Int. Arch. Allergy 12, 89–97 (1958)
Drew, G.M.: Effects of α-adrenoceptor agonists and antagonists on pre-and postsynaptically located α-adrenoceptors. Europ. J. Pharmacol. 36, 313–320 (1976)
D’Silva, J.L.: Action of adrenaline-like substances on the serum potassium. J. Physiol. (Lond.) 108, 218–225 (1949)
Dubocovich, M.L., Langer, S.Z.: Negative feedback regulation of noradrenaline release by nerve stimulation in the perfused cat’s spleen: differences in potency of phenoxybenzamine in blocking the pre-and post-synaptic adrenergic receptors. J. Physiol. (Lond.) 237, 505–519 (1974)
Dukes, H.T., Vieth, R.G.: Cerebral arteriography during migraine prodrome and headache. Neurology (Minneap.) 14, 636–639 (1966)
Dumke, P.R., Schmidt, C.F.: Quantitative measurements of cerebral blood flow in the macaque monkey. Amer. J. Physiol. 138, 421–431 (1943)
Dunér, H., Granath, A., Klingenström, P.: The effect of ergotamine on blood pressure and cardiac output during spinal anaesthesia in man. Acta anaesthesiol. scand. 4, 5–11 (1960)
Duret, R.-L.: Action des dérivés d-hydrogénés de l’ergot dans hypertension artérielle. Acta clin. belg. 6, 85–106 (1951)
Eben-Moussi, E., Allain, P., Van den Driessche, J.: Hydergine et troubles du rythme cardiaque provoqués par la K-strophantine. Thérapie 21, 375–378 (1966)
Echt, M., Lange, L.: Experimentelle Untersuchungen iiber die Wirkung venentonisierender Pharmaka auf das Niederdrucksystem des Menschen. In: Das Orthostasesyndrom. 5. Rothenburger Gespräch 25./26.5.73. Dengler, H.J. (ed.), pp. 109–123. Stuttgart-New York: Schattauer 1974
Ehringer, H.: Zur Wirkung von reinem Dihydroergocristin auf Extremitätendurchblutung und periphere Venentonisierung des Menschen. Int. J. clin. Pharmacol. Biopharm. 3, 81–86 (1970)
Elek, S.R., Hoffman, I., Griffith, G.C., Leik, D.W.: The cardiac effects of dihydroergocornine (DHO-180). Arch. int. Pharmacodyn. 100, 249–264 (1955)
Eliasson, S., Folkow, B., Lindgren, P., Uvnäs, B.: Activation of sympathetic vasodilator nerves to the skeletal muscles in the cat by hypothalamic stimulation. Acta physiol. scand. 23, 333–351 (1951)
Eliasson, S., Lindgren, P., Uvnäs, B.,: Representation in the hypothalamus and the motor cortex in the dog of the sympathetic vasodilator outflow to the skeletal muscles. Acta physiol. scand. 27, 18–37 (1952)
Elkind, A.H., Friedman, A.P., Grossman, I.: Cutaneous blood flow in vascular headaches of the migraine type. Neurology (Minneap.) 14, 24–30 (1964)
Enero, M.A., Langer, S.Z.: Inhibition by dopamine of 3H-noradrenaline release elicited by nerve stimulation in the isolated cat’s nictitating membrane. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 289, 179–203 (1975)
Erlij, D., Mendez, C.: Adrenergic actions on heart rate, atrioventricular refractory period and intraventricular conduction in dogs. Arch. int. Physiol. Biochim. 72, 44–65 (1964)
Erlij, D., Cefrangolo, R., Valadez, R.: Adrenotropic receptors in the frog. J. Pharmacol. exp. Ther. 149, 65–70 (1965)
Euler, U.S. v., Hesser, C.M.: Beobachtungen über Hemmungen der Sinusdruckreflexe durch Ergotamin, Dihydroergotamin und Hyperventilation. Schweiz. med. Wschr. 77, 20–21 (1947)
Euler, U.S. v., Liljestrand, G.: The role of the chemoreceptors of the sinus region for the occlusion test in the cat. Acta physiol. scand. 6, 319–323 (1943)
Euler, U.S. v., Liljestrand, G.: The regulation of the blood pressure with special reference to muscular work. Acta physiol. scand. 12, 279–300 (1946)
Euler, U.S. v., Schmiterlow, C.G.: The action of ergotamine on the chemical and mechanical reflexes from the carotid sinus region. Acta physiol. scand. 8, 122–133 (1944)
Eyzaguirre, C., Lewin, J.: Chemoreceptor activity of the carotid body of the cat. J. Physiol. (Lond.) 159, 222–237 (1961)
Fahim, I., Botros, M., Merhom, K., Saad, Y.: The central hypotensive effects of ergotamine and its possible mechanism. Ain Shams Med. 25, 355–357 (1974)
Fanchamps, A., Doepfner, W., Weidmann, H., Cerletti, A.: Pharmakologische Charakterisierung von Deseril, einem Serotonin-Antagonisten. Schweiz. med. Wschr. 90, 1040–1046 (1960)
Fanciullacci, M., Granchi, G., Sicuteri, F.: Ergotamine and methysergide as serotonin partial agonists in migraine. Headache 16, 226–231 (1976)
Farnebo, L.O., Hamberger, B.: Drug-induced changes in the release of (3H)-noradrenaline from field stimulated rat iris. Brit. J. Pharmacol. 43, 97–106 (1971)
Fay, T.: Mechanism of headache. Trans. Amer. neurol. Ass. 62, 74–77 (1936)
Fehr, T., Stütz, P., Stadler, P.A., Hummel, R., Salzmann, R.: Antihypertensiv wirksame Harnstoffderivate des 8β-aminomethyl-6-methyl-ergolens. Europ. J. Med. Chem. 9, 597–601 (1974)
Ferreira, S.H.: Prostaglandins, aspirin-like drugs and analgesia. Nature New Biol. 240, 200–203 (1972)
Fey, K.H., Herzfeld, U., Saggau, W., Oehlschläger, M.: Postoperative Thromboprophylaxe durch Tonisierung des kaudalen Venensystems. Med. Klin. 70, 1553–1558 (1975)
Fitzgerald, W.J.: Methergine: a study of its effect on blood pressure. Obstet. and gynec. 8, 167–169 (1956)
Fog-Møller, F., Kemp-Genefke, I., Bryndum, B.: Changes in concentration of catecholamines in blood during spontaneous migraine attacks and reserpine-induced attacks. The Migraine Trust International Symposium, London, p. 10 (16–17 Sept. 1976)
Folkow, B.: Nervous control of blood vessels. Physiol. Rev. 35, 629–663 (1955)
Folkow, B., Uvnäs, B.: Do adrenergic vasodilator nerves exist? Acta physiol. scand. 20, 329–337 (1950)
Fox, R.H., Goldsmith, R., Kidd, D.J., Lewis, G.P.: Bradykinin as a vasodilator in man. J. Physiol. (Lond.) 157, 589–602 (1961)
Franke, H.: Die pharmakologische Beeinflussung der kardialen Form des hypersensitiven Carotissinus-Syndroms durch hydrierte Mutterkornalkaloide. Z. exp. Med. 116, 463–477 (1950)
Freis, E.D., Stanton, J.R., Litter, J., Culbertson, J.W., Halperin, M.H., Moister, F.C., Wilkins, R.W.: The hemodynamic effects of hypotensive drugs in man. II. Dihydroergocornine. J. clin. Invest. 28, 1387–1402 (1949)
Freis, E.D., Stanton, J.R., Finnerty, F.A., Schnaper, H.W., Johnson, R.L., Rath, C.E., Wilkins, R.W.: The collapse produced by venous congestion of the extremities or by venesection following certain hypotensive agents. J. clin. Invest. 30, 435–444 (1951)
Freudiger, A., Rothlin, E.: Ueber die Wirkung der naturlichen und dihydrierten Mutterkornalkaloide auf das isolierte Froschherz. Arch. int. Pharmacodyn. 78, 445–455 (1949)
Friedman, M.D., Friedman, D.A.: Dihydroergotamine (DHE-45) in the treatment of migraine: Preliminary clinical observations. Ohio med. J. 41, 1099–1100 (1945)
Gaddum, J.H., Paasonen, M.K.: The use of some molluscan hearts for the estimation of 5-hydroxytryptamine. Brit. J. Pharmacol. 10, 474–483 (1955)
Ganter, G.: Ueber die Ausschaltung des vegetativen Nervensystems am Kreislauf. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 113, 129–150 (1926)
Gatzek, H., Matthies, K., Mechelke, K.: Untersuchungen uber das Wirkungsbild der Mutterkornalkaloide Ergotamin, Dihydroergotamin und Dihydroergocornin am gesunden Menschen. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 207, 720–730 (1949)
Gernandt, B., Zotterman, Y.: The splanchnic efferent outflow of impulses in the light of ergotamine action. Acta physiol. scand. 11, 301–317 (1946)
Gernandt, B., Liljestrand, G., Zotterman, Y.: Efferent impulses in the splanchnic nerve. Acta physiol. scand. 11, 230–247 (1946)
Gillis, R.A.: Cardiac sympathetic nerve activity: changes induced by ouabain and propranolol. Science 166, 508–510 (1969)
Gillis, R.A., Dionne, R.A., Standaert, F.G.: Suppression by clonidine (St-155) of cardiac arrhythmias induced by digitalis. J. Pharmacol. exp. Ther. 182, 218–226 (1972)
Ginzel, K.H.: The effect of (+)-lysergic acid diethylamide and other drugs on the carotid sinus reflex. Brit. J. Pharmacol. 13, 250–259 (1958)
Ginzel, K.H., Kottegoda, S.R.: A study of the vascular actions of 5-hydroxytryptamine, tryptamine, adrenaline and noradrenaline. Quart. J. exp. Physiol. 38, 225–231 (1953)
Glasser, A.: Some pharmacological actions of d-lysergic acid methyl carbinolamide. Nature (Lond.) 189, 313–314 (1961)
Goetz, R.H.: The action of dihydroergocornine on the circulation with special reference to hypertension. Lancet I, 510–514 (1949)
Goetz, R.H.: The effect of intra-arterial injections of Hydergine and dihydroergocornine on the peripheral circulation in man. Circulation 13, 63–74 (1956)
Goetz, R.H., Katz, A.: The adrenolytic action of dihydroergocornine in man. Lancet 256, 560–563 (1949)
Goldberg, L.I.: Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol. Rev. 24, 1–29 (1972)
Goldman, H., Fischer, R., Nicolov, N., Murphy, S.: Lysergic acid diethylamide affects blood flow to specific areas of the conscious rat brain. Experientia (Basel) 31, 328–330 (1975)
Gottstein, U., Niedermauer, W., Bernsmeier, A.: Die Gehirndurchblutung unter dem Einfluß vasoaktiver Substanzen. Z. ges. exp. Med. 131, 430–439 (1959)
Govier, W.C.: Myocardial alpha adrenergic receptors and their role in the production of a positive inotropic effect by sympathomimetic agents. J. Pharmacol. exp. Ther. 159, 82–90 (1968)
Govier, W.C., Mosal, N.C., Whittington, P., Broom, A.H.: Myocardial alpha and beta adrenergic receptors as demonstrated by atrial functional refractory period changes. J. Pharmacol. exp. Ther. 154, 255–263 (1966)
Graham, J.R., Wolff, H.G.: Mechanism of migraine headache and action of ergotamine tartrate. Proc. Ass. Res. nerv. ment. Dis. 18, 638–669 (1937)
Graham, J.D.P., Khalidi, A.I.: The actions of d-lysergic acid diethylamide. J. Fac. Med. Baghdad 18, 1–10 (1954)
Greenacre, J.K., Teychenne, P.F., Petrie, A., Calne, D.B., Leigh, P.N., Reid, J.L.: The cardiovascular effects of bromocriptine in parkinsonism. Brit. J. clin. Pharmacol. 3, 571–574 (1976)
Greenberg, M.J.: Structure-activity relationship of tryptamine analogues on the heart of Venus mercenaria. Brit. J. Pharmacol. 15, 375–388 (1960a)
Greenberg, M.J.: The response of the Venus heart to catecholamines and high concentrations of 5-hydroxytryptamine. Brit. J. Pharmacol. 15, 365–374 (1960b)
Guimarães, S., Osswald, W.: Adrenergic receptors in the veins of the dog. Europ. J. Pharmacol. 5, 133–140 (1969)
Guyton, A.C.: Textbook of medical physiology. 2nd ed., pp. 398–400. Philadelphia-London: W.B. Saunders Co. 1961
Gyermek, L., Sztanyik, L., Lang, E.: The adrenolytic and sympathicolytic efficiency of ergot alkaloids. Acta physiol. Acad. Sci. hung. 1, 65–74 (1950)
Haddy, F.J., Gordon, P., Emanuel, D.A.: The influence of tone upon responses of small and large vessels to serotonin. Circulat. Res. 7, 123–130 (1959)
Hafkenschiel, J.H., Crumpton, C.W., Moyer, J.H.: The effect of intramuscular dihydroergocornine on the cerebral circulation in normotensive patients. J. Pharmacol. exp. Ther. 98, 144–146 (1950a)
Hafkenschiel, J.H., Crumpton, C.W., Moyer, J.H., Jeffers, W.A., Hanley, B.F., Harned, S.C.: The effects of dihydroergocornine on the cerebral circulation of patients with essential hypertension. J. clin. Invest. 29, 408–411 (1950b)
Haley, T.J., McCormick, W.G.: Effect of ergotamine and hydergine on muscle blood flow in the dog. Fed. Proc. 14, 348–349 (1955)
Haley, T.J., McCormick, W.G.: Comparison of the effect of ergotamine and hydergine on muscle and skin blood flow in the anaesthetised dog. J. Pharmacol. exp. Ther. 117, 406–413 (1956)
Haley, T.J., Andem, M.R., Liebig, C.: Comparison between capillary effects produced by topical application and intravenous injection of ergot alkaloids. Arch. int. Pharmacodyn. 98, 373–378 (1954)
Halmágyi, D.F.J., Colebatch, H.J.H.: Serotonin-like cardiorespiratory effects of a serotonin antagonist. J. Pharmacol. exp. Ther. 134, 47–52 (1961)
Halmágyi, B., Felkai, J., Ivanyi, J., Hetényi, J.Jr.: The role of the nervous system in the maintainance of venous hypertension in heart failure. Brit. Heart J. 14, 101–111 (1952)
Halmágyi, D., Iványi, J., Felkai, B., Zsótér, T. Tényi, M., Szücs, Z.: The effect of dihydroergotamine and Hydergin on pulmonary arterial pressure in man. Scand. J. clin. Lab. Invest. 5, 85–89 (1953)
Hammerschmidt, D., Odenthal, F.: Ueber die Wirkung der hydrierten Mutterkornalkaloide auf den arteriellen und venösen Blutdruck. Z. Kreisl.-Forsch. 39, 150–160 (1950)
Handley, C.A., Moyer, J.H.: Changes in sodium and water excretion produced by vaso-active and by ganglionic and adrenergic blocking agents. Amer. J. Physiol. 178, 309–314 (1954)
Harich, B.K.S., Nissen, H., Stauch, M.: Die Alpha-Sympathikolyse im arteriellen und venösen Kreislaufschenkel nach Hyderginê. Herz/Kreisl. 7, 194–198 (1975)
Harmel, M.H., Hafkenschiel, J.H., Austin, G.M., Crumpton, C.W., Kety, S.S.: The effect of bilateral stellate ganglion block on the cerebral circulation in normotensive and hypertensive patients. J. clin. Invest. 28, 415–418 (1949)
Harri, M.N.E.: Temperature-dependent sensitivity of adrenoceptors in the toad heart. Acta Pharmacol. toxicol. (Kbh.) 33, 273–279 (1973)
Harris, A.S.: Delayed development of ventricular ectopic rhythms following experimental coronary occlusion. Circulation 1, 1318–1328 (1950)
Harris, A.S., Bisteni, A.: Effects of sympathetic blockade drugs on ventricular tachycardia resulting from myocardial infarction. Amer. J. Physiol. 181, 559–566 (1955)
Harris, A.S., Estandia, A., Tillotson, R.F.: Ventricular ectopic rhythms and ventricular fibrillation following cardiac sympathectomy and coronary occlusion. Amer. J. Physiol. 165, 505–512 (1951)
Harris, A.S., Bisteni, A., Russell, R.A., Brigham, J.C., Firestone, J.E.: Excitatory factors in ventricular tachycardia resulting from myocardial ischaemia. Potassium a major excitant. Science 119, 200–203 (1954)
Harris, P., Bishop, J.M., Segel, N.: The effects of dihydroergotamine tartrate on the pulmonary and systemic circulations in man. Clin. Sci. molec. Med. 25, 443–447 (1963)
Hartman, M.M.: Parenteral use of dihydroergotamine in migraine. Ann. Allergy 3, 440–442 (1945)
Harvey, S.C., Nickerson, M.: Adrenergic inhibitory function in the rabbit: epinephrine reversal and isopropylnorepinephrine vasodepression. J. Pharmacol. exp. Ther. 108, 281–291 (1953)
Harvey, S.C., Wang, C.Y., Nickerson, M.: Blockade of epinephrine-induced hyperglycemia. J. Pharmacol. exp. Ther. 104, 363–376 (1952)
Harvey, S.C., Copen, E.G., Eskelson, D.W., Graff, S.R., Poulsen, L.D., Rasmussen, D.L.: Autonomic pharmacology of the chicken with particular reference to adrenergic blockade. J. Pharmacol. exp. Ther. 112, 8–22 (1954)
Hazard, R., Beauvallet, M., Giudicelli, R., Mouillé, P., Renier-Cornec, A.: Modifications apportées par divers adrénalinotoniques et adrénalinoverseurs aux effect tensionnels de l’isoprénaline (Aleudrineê) chez le chat. Arch. int. Pharmacodyn 143, 331–336 (1963)
Heck, J.: Dihydroergotamin bei orthostatischer Dysregulation. Med. Klin. 66, 601–604 (1971)
Heimdal, À., Nordenfelt, O.: The effect of Hydergine on the electrocardiogram. Cardiologia (Basel) 23, 361–372 (1953)
Heise, A.: Hypotensive action by central a-adrenergic and dopaminergic receptor stimulation. In: New antihypertensive drugs. Scriabine, A., Sweet, C.S. (eds.), New York: Spectrum Publications, Inc. 1976
Helke, C.J., Souza, J.D., Hamilton, B.L., Morgenroth, V.H., Gillis, R.A.: Evidence for a role of central serotonergic neurones in digitalis-induced cardiac arrhythmias. Nature (Lond.) 263, 246–248 (1976)
Herwick, R.P., Linegar, C.R., Koppanyi, T.: The effect of anaesthesia on the vasomotor reversal. J. Pharmacol. exp. Ther. 65, 185–190 (1939)
Heyck, H.: Neue Beiträge zur Klinik und Pathogenese der Migräne, pp. 28–37, Stuttgart: Thieme 1956
Heyck, H.: Serotoninantagonisten in der Behandlung der Migräne und der Erythroprosopalgie Bings oder des Horton-Syndroms. Schweiz. med. Wschr. 90, 203–209 (1960)
Heyck, H.: Pathogenesis of migraine. Res. Clin. Stud. Headache 2, 1–28, Basel: Karger 1969
Heymans, C., Bouckaert, J.J.: Au sujet de l’action vasomotrice et vasculaire de l’ergotamine. Arch. int. Pharmacodyn 46, 129–136 (1933)
Heymans, C., Heuvel-Heymans, G. van den: Action of drugs on arterial wall of carotid sinus and blood pressure. Arch. int. Pharmacodyn. 83, 520–528 (1950)
Heymans, C., Neil, E.: Reflexogenic areas of the cardiovascular system. London: J. and A. Churchill Ltd. 1958
Heymans, C., Regniers, P.: Sur l’action vasculaire et sympathique de l’ergotamine et de l’ergotinine. Arch. int. Pharmacodyn. 33, 236–249 (1927)
Heymans, C., Regniers, P.: Influence de l’ergotamine sur les réflexes cardio-vasculaires du sinus carotidien. Arch. int. Pharmacodyn. 36, 116–121 (1929)
Heymans, C., Regniers, P., Bouckaert, J.J.: Ergotamine et réflexes vasomoteurs. La localisation de l’action de l’ergotamine sur les réflexes vasomoteurs du sinus carotidien. Arch. int. Pharmacodyn. 39, 213–224 (1930)
Heymans, C., Bouckaert, J.J., Dautrebande, L.: Sinus carotidien et refléxes respiratoirs. III Sensibilité des sinus carotidiens aux substances chimiques. Action stimulant respiratoire réflexe du sulfure de sodium, du cyanure de potassium de la nicotine et de la lobéline. Arch. int. Pharmacodyn. 40, 54–91 (1931)
Heymans, C., Bouckaert, J.J., Moraes, A.: Inversion par l’ergotamine de l’action vasoconstrictice des ‚vasotonines ‘du sang défibriné. Arch. int. Pharmacodyn. 43, 468–479 (1932a)
Heymans, C., Bouckaert, J.J., Euler, U.S. v., Dautrebande, L.: Sinus carotidiens et reflexes vasomoteurs. Arch. int. Pharmacodyn. 43, 86–110 (1932b)
Hökfelt, T., Fuxe, K.: On the morphology and the neuroendocrine role of the hypothalamic catecholamine neurons. In: Brain Endocrine Interaction. Knigge, K.M., Scott, D.E., Weindl, A. (eds.), pp. 181–223, Basel: S. Karger 1972
Hör, G., Buttermann, G., Theisinger, W., Pabst, H.W.: Prevention of postoperative thromboembolism by various treatments. Controlled clinical trial in 632 patients using 125I-fibrinogen-uptake-test and lung-perfusion-scans in patients with deep venous thrombosis. Europ. J. nucl. Med. 1, 197–203 (1976)
Hofmann, A.: Ergot — a rich source of pharmacologically active substances. In: Plants in the development of modern medicine. Swain, T. (ed.), pp. 235–260, Cambridge, Mass.: Harvard University Press 1972
Horton, B.T., Peters, G.A., Blumenthal, L.S.: A new product in the treatment of migraine: a preliminary report. Proc. Mayo Clin. 20, 241–248 (1945)
Immerwahr, P.: Über die Wirkung des Ergotamin auf Puis, Blutdruck und Blutzucker und ihre Beeinflussung durch Atropin. Med. Klin. 23, 1–3 (1927)
Ingvar, D.H.: Discussion of Professor Marshall’s paper: The regulation of cerebral blood flow; its relationship to migraine. Arch. Neurobiol. 37, (Extranr.), 21–25 (1974)
Ingvar, D.H.: Pain in the brain and migraine. Hemicrania 7, 2–6 (1976)
Ingvar, D.H., Söderberg, U.: The effect of LSD-25 upon the cerebral blood flow and EEG in cats. Experientia (Basel) 12, 427–429 (1956)
Innes, I.R.: Identification of the smooth muscle excitatory receptors for ergot alkaloids. Brit. J. Pharmacol. 19, 120–128 (1962)
Isbell, H.: Comparison of the reactions induced by psilocybin and LSD-25 in man. Psychopharmacologia 1, 29–38 (1959)
Johnson, A.M., Loew, D.M., Vigouret, J.M.: Central dopaminergic stimulant properties of bromocriptine in comparison to apomorphine, d-amphetamine and L-DOPA. Brit. J. Pharmacol. 56, 59–68 (1976)
Kangasniemi, P., Sonninen, V., Rinne, U.K.: Excretion of free and conjugated 5-HIAA and VMA in urine and concentration of 5-HIAA and HVA in CSF during migraine attacks and free intervals. Headache 12, 62–65 (1972)
Kappert, A.: Untersuchungen über die Wirkungen neuer dihydrierter Mutterkornalkaloide bei peripheren Durchblutungsstörungen und Hypertonie. Helv. med. Acta, Suppl. 22, 27–64 (1949a)
Kappert, A.: Untersuchungen über die Wirkungen neuer dihydrierter Mutterkornalkaloide bei peripheren Durchblutungsstörungen und Hypertonie. Helv. med. Acta, Suppl. 22, 95–126 (1949b)
Kappert, A., Hadorn, W.: Experimental and therapeutic investigations with certain new hydrogenated ergot alkaloids in peripheral vascular disorders. Angiology 1, 520–529 (1950)
Kappert, A., Sutton, G.C., Reale, A., Skoglund, K.-H.: Untersuchungen über die Wirkung von Hydergin (CCK) auf die durch Noradrenalin ausgelöste Hypertension. Cardiologia (Basel) 16, 129–144 (1950)
Karlsberg, P., Elliott, H.W., Adams, J.E.: Effect of various pharmacologic agents on cerebral arteries. Neurology (Minneap.) 13, 772–778 (1963)
Karp, D., Rinzler, S.H., Travell, J.: Effects of ergometrine (ergonovine) on the isolated atherosclerotic heart of the cholesterol-fed rabbit. Brit. J. Pharmacol. 15, 333–344 (1960)
Karr, N.W.: Circulatory and adrenolytic actions of DHE and DHO. Fed. Proc. 7, 232 (1948)
Katz, L.N., Lindner, E.: The reaction of the coronary vessels to drugs and other substances. J. Amer. med. Ass. 113, 2116–2119 (1939)
Kaye, S.B., Shaw, K.M., Ross, E.J.: Bromocriptine and hypertension. Lancet I, 1176–1177 (1976)
Kimball, R.W., Friedman, A.P., Vallejo, E.: Effect of serotonin in migraine patients. Neurology (Minneap.) 10, 107–111 (1960)
Kirpekar, S.M., Puig, N.: Effect of flow-stop on noradrenaline release from normal spleens and spleens treated with cocaine, phentolamine or phenoxybenzamine. Brit. J. Pharmacol. 43, 359–369 (1971)
Klingenberg, I.: Measurement of uterine blood flow in non-pregnant women by electromagnetic flowmeter. Acta obstet. gynec. scand. 52, 317–321 (1973)
Knapp, F.M., Hyman, C., Bercel, N.A.: A method for the estimation of regional cerebral blood flow. Yale J. Biol. Med. 28, 363–371 (1955)
Kofler, E.: Ueber die Mikrozirkulation an der Portio vaginalis uteri. Wien. klin. Wschr. 84, Suppl. 3, 3–16 (1972)
Kohn, R.: Ueber den Mechanismus der Blutdruckregulation im indifferenten Bade. Z. ges. exp. Med. 85, 483–494 (1932)
Konzett, H., Rothlin, E.: Investigations on the hypotensive effect of the hydrogenated ergot alkaloids. Brit. J. Pharmacol. 8, 201–207 (1953)
Koopmans, S.: The function of the blood vessels in the brain. II. The effects of some narcotics, hormones and drugs. Arch. néerl. Physiol. 24, 250–266 (1939)
Krai, U.A.: Neurologische Erfahrungen mit ‚Dihydroergotamine‘. Schweiz. Arch. Neurol. Psychiat. 62, 128–150 (1948)
Krause, D.: Die Wirkung von Ergotamin und Hydergin auf die zentrale Kreislaufregulation. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 222, 212–214 (1954)
Krause, D., Schmidtke-Ruhnau, D., Moursi Ali, H.: Zentrale Sympathikusdämpfung und adrenolytische Wirkung genuiner und hydrierter Mutterkornalkaloide. Dtsch. tierärztl. Wschr. 78, 292–294 (1971)
Krstić, M.K., Djurković, D.: Hypertension mediated by the activation of the rat brain 5-hydroxytryptamine receptor sites. Experientia (Basel) 32, 1187–1189 (1976)
Kühns, K.: Untersuchungen über die Wirkung eines neuen Sympathicolyticums (Hydergin) und anderer vegetativer Pharmaka auf Elektrokardiogramm und Herzfrequenz des wachen Kaninchens. Helv. med. Acta 16, 90–109 (1949)
Kühns, K.: Zur Behandlung ventrikulärer Tachykardien. Z. Kreisl.-Forsch. 40, 415–422 (1951)
Kunos, G.: Thyroid hormone-dependent interconversion of myocardial α-and β-adrenoceptors in the rat. Brit. J. Pharmacol. 59, 177–189 (1977)
Kunos, G., Nickerson, M.: Temperature-induced interconversion of α-and β-adrenoceptors in the frog heart. J. Physiol. (Lond.) 256, 23–40 (1976)
Kunos, G., Szentiványi, M.: Evidence favouring the existence of a single adrenergic receptor. Nature (Lond.) 217, 1077–1078 (1968)
Kunos, G., Yong, M.S., Nickerson, M.: Transformation of adrenergic receptors in the myocardium. Nature New Biol. 241, 119–120 (1973)
Laddu, A.R., Somani, P.: Direct and beta-adrenoceptor blocking effects of 4-(2-hydroxy-3-isopropylaminopropoxy)-indol (LB46) on myocardial hemodynamics. Arch. int. Pharmacodyn. 196, 5–15 (1972)
Lake, C.L.: Vasopressor effects of intravenous and intramuscular injections of methergine in the postpartum patient. Obstet. and Gynec. 4, 308–310 (1954)
Lance, J.W.: Mechanism and management of headache, 2nd ed., pp. 113–133. London: Butterworths 1973
Lance, J.W., Anthony, M.: Thermographic studies in vascular headache. Med. J. Aust. 1, 240–243 (1971)
Landesman, R., Mendelsohn, B.: The uterine omentum of the rat and its response to vasoconstrictor drugs. Amer. J. Obstet. Gynec. 72, 84–92 (1956)
Landgren, S., Neil, E.: The contribution of carotid chemoreceptor mechanisms to the rise of blood pressure caused by carotid occlusion. Acta physiol. scand. 23, 152–157 (1951)
Lands, A.M., Luduena, F.P., Grant, J.I., Ananenko, E., Tainter, M.L.: Reversal of the depressor action of N-isopropylarterenol (isuprel) by ergotamine and ergotoxine. J. Pharmacol. exp. Ther. 100, 234–297 (1950)
Lang, E., Jansen, W., Pfaff, W.: Orthostatische Hypotonie bei älteren Menschen. Häufigkeit und Therapie. Med. Klin. 70, 1976–1981 (1975)
Lange, L., Echt, M.: Vergleichende Untersuchungen über venentonisierende Pharmaka. Fortschr. Med. 90, 1161–1164 (1972)
Langer, S.Z.: Presynaptic regulation of norepinephrine release elicited by nerve stimulation. Life Sci. 13, xcvii–xcix (1973)
Langer, S.Z.: Presynaptic regulation of catecholamine release. Biochem. Pharmacol. 23, 1793–1800 (1974)
Langer, S.Z., Adler, E., Enero, M.A., Stefano, F.J.E.: The role of the alpha receptor in regulating noradrenaline overflow by nerve stimulation. Proc. XXVth. Int. Congr. Physiol. Sci., München, p. 335 (1971)
Langer, S.Z., Enero, M.A., Adler-Graschinsky, E., Stefano, F.J.E.: The role of the alpha receptor in the regulation of transmitter overflow elicited by stimulation. V Int. Congr. Pharmacol. San Fransisco, USA, 23/28th July, 1972, Abstr. No. 802
Lasch, F.: Über die Beeinflussung der Nierenclearance durch Hyderginbehandlung. Cardiologia (Basel) 24, 155–166 (1954)
Lassen, N.A., Hoedt-Rasmussen, K., Sørensen, S.C., Skinhøj, E., Cronquist, S., Bodforss, B., Eng, E., Ingvar, D.H.: Regional cerebral blood flow in man determined by krypton85. Neurology (Minneap.) 13, 719–727 (1963)
Laubie, M., Delbarre, B., Bogaievsky, D., Bogaievsky, Y., Tsoucaris-Kupfer, E., Senon, D., Schmitt, H., Schmitt, H.: Pharmacological evidence for a central α-sympathomimetic mechanism controlling blood pressure and heart rate. Circulat. Res. 38, Suppl. II, 35–41 (1976)
Leist, K.H., Grauwiler, J.: Ergometrine and uteroplacental blood supply in pregnant rats. Teratology 10, 316 (1974)
Lennox, W.G.: Ergonovine versus ergotamine as a terminator of migraine headaches. Amer. J. med. Sci. 195, 458–468 (1938)
Lennox, W.G., Gibbs, E.L., Gibbs, F.A.: Effect of ergotamine tartrate on the cerebral circulation of man. J. Pharmacol. exp. Ther. 53, 113–119 (1935)
Levy, B., Ahlquist, R.P.: An analysis of adrenergic blocking activity. J. Pharmacol. exp. Ther. 133, 202–210 (1961)
Ley, J., De La Fontaine-Verwey, B.-C.: A propos de certaines réactions des vaisseaux cerebraux du lapin dans leurs rapports avec les conditions humorales et avec leur innervation sympathique. C.R. Soc. Biol. (Paris) 101, 478–480 (1929)
Liljestrand, A.: Interaction of ergotamine and carbon dioxide on blood pressure and respiration. Acta physiol. scand. 15, 198–206 (1948)
Lindgren, P., Uvnäs, B.: Postulated vasodilator centre in the medulla oblongata. Amer. J. Physiol. 176, 68–76 (1954)
Lindgren, P., Uvnäs, B.: Vasoconstrictor inhibition and vasodilator activation — two functionally separate vasodilator mechanisms in the skeletal muscles. Acta physiol. scand. 33, 108–119 (1955)
Lipton, B., Gittler, R.D., Slotnik, H.O., Rockaway, F.: Cardiovascular effects of oxytocin injection (USP) synthetic, prepared oxytocin and the ergot alkaloids. N.Y. St. J. Med. 60, 4006–4015 (1960)
Lockett, M.F., Wadley, R.: Renal actions of dihydroergocristine and of phentolamine in anaesthetised cats. Brit. J. Pharmacol. 37, 595–608 (1969)
Loewi, O., Navratil, E.: Ueber den Mechanismus der Vaguswirkung von Physostigmin und Ergotamin. Pflügers Arch. ges. Physiol. 214, 689–696 (1926)
Logaras, G.: Further studies of the pulmonary arterial blood pressure. Acta physiol. scand. 14, 120–135 (1947)
Lohmann, F.W., Gotzen, R., Ungewiss, U.: Der Einfluss von Dihydroergotamin (Dihydergot) auf die Kreislaufveränderungen und die Funktion des sympathischen Nervensystems in Orthostase. Med. Welt 26, 1416–1420 (1975)
Long, J.P., Heintz, S., Cannon, J.G., Kim, J.: Inhibition of the sympathetic nervous system by 5,6-dihydroxy-2-dimethylamino-tetralin (M-7), apomorphine and dopamine. J. Pharmacol. exp. Ther. 192, 336–342 (1975)
Longo, T., Santa, A.: The effects of catecholamines on renal artery flow before and after alpha-receptor blockade. Comparative experimental research on the conscious and anaesthetised dog. J. cardiovasc. Surg. 9, 195–200 (1968)
Lottenbach, K.: Sympathikolyse und Erregbarkeit der Karotissinusreflexe am Menschen. Z. Kreisl.-Forsch. 42, 98–103 (1953)
Lübke, K.O.: Der Einfluß von Dihydroergotamin auf Herzfrequenz, Blutdruck und Hautdurchblutung während orthostatischer Belastung. Herz-Kreislauf 4, 52–55 (1972)
Lubsen, N.: Experimental studies on the cerebral circulation of the unanaesthetised rabbit. III. The action of ergotamine tartrate and of some vasodilator drugs. Arch. néerl. Physiol. 25, 361–365 (1940)
Lugaresi, E., Rebucci, G.G.: Prime esperienze sull’azione di alcuni farmaci alia luce de registrazioni reografiche contemperanee cerebrali e periferiche. G. Psichiat. Neuropat. 90, 881–895 (1962)
Manning, G.W., Caudwell, G.C.: The effect of demerol, ergotamine and dihydroergotamine on mortality after coronary occlusion in dogs. Brit. Heart J. 9, 85–95 (1947)
Manz, M., Felix, W.: Effects of dihydroergotamine (DHE) on the capacitance and resistance vessels of the cat hindleg (chloralose anaesthesia). Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 282 (Suppl.), R62 (1974)
Marques, M.G., Rato, J.A.: Quelques action des alcaloides hydrogenes de Tergot de seigle sur l’appareil cardio-vasculaire. Cardiologia (Basel) 24, 196–206 (1954)
Marsh, D.F., Liere, E.J. van: The effect of adrenergic blocking agents on the vasoconstriction produced by acute oxygen lack. J. Pharmacol. exp. Ther. 44, 221–224 (1948)
Mathew, N.T., Hrastnik, F., Meyer, J.S.: Regional cerebral blood flow in the diagnosis of vascular headache. Headache 15, 252–260 (1976)
Mazzella, H.: On the reactivity of the wall of the carotid sinus. Arch. int. Pharmacodyn. 116, 37–44 (1958)
McCall, M.L., Taylor, H.W., Read, A.W.: The action of hydergine on the circulation and metabolism of the brain in toxemia of pregnancy. Amer. J. med. Sci. 226, 537–540 (1953)
McCulloch, M.W., Rand, M.J., Story, D.F.: Inhibition of 3H-noradrenaline release from sympathetic nerves of guinea-pig atria by a presynaptic α-adrenoceptor mechanism. Brit. J. Pharmacol. 46, 523P–524P (1972)
McCulloch, M.W., Rand, M.J., Story, D.F.: Evidence for a dopaminergic mechanism for modulation of adrenergic transmission in the rabbit ear artery. Brit. J. Pharmacol. 49, 141P (1973)
McDowell, R.J.S.: Capacity effects from the carotid sinus. J. Physiol. (Lond.) 84, 24P (1935)
McEachern, G.G., Manning, G.W., Hall, G.E.: Sudden occlusion of coronary arteries following removal of cardiosensory pathways. Arch. int. Med. 65, 661–670 (1940)
Meirsman-Roobroeck, G.C.: The protective action of parpanit, diparcol and some other drugs against chloroform-adrenaline ventricular fibrillation. Arch. int. Pharmacodyn. 83, 353–385 (1950)
Mellander, S.: Comparative studies on the adrenergic neuro-hormonal control of resistance and capacitance blood vessels in the cat. Acta physiol. scand. 50, suppl. 176, 1–86 (1960)
Mellander, S.: Comparative effects of acetylcholine, butyl-norsynephrine (vasculat), noradrenaline and ethyl-adrianol (Effortil) on resistance, capacitance and pre-capillary sphincter vessels and capillary filtration in cat skeletal muscle. Angiology 3, 77–99 (1966)
Mellander, S., Johansson, B.: Control of resistance, exchange and capacitance functions in the peripheral circulation. Pharmacol. Rev. 20, 117–196 (1968)
Mellander, S., Nordenfelt, I.: Comparative effects of dihydroergotamine and noradrenaline on resistance, exchange and capacitance functions in the peripheral circulation. Clin. Sci. 39, 183–201 (1970)
Mendez, C., Aceves, J., Mendez, R.: Inhibition of adrenergic cardiac acceleration by cardiac glycosides. J. Pharmacol. exp. Ther. 131, 191–198 (1961)
Meriel, P., Bollinelli, R., Calazel, P., Cassagneau, J.: Epreuve á l’hydergine et pressions pulmonaires. Arch. Mai. Coeur 46, 329–340 (1953)
Meyer, J.S., Yoshida, K., Sakamoto, K.: Autonomic control of cerebral blood flow measured by electromagnetic flowmeters. Neurology (Minneap.) 17, 638–648 (1967)
Micheli, P. de, Glasser, A.H.: The effects of catecholamines and adrenoceptor blocking drugs on the canine peripheral lymph flow. Brit. J. Pharmacol. 53, 499–504 (1975)
Moe, G.D., Malton, S.D., Rennick, B.R., Freyburger, W.A.: The role of arterial pressure in the induction of idioventricular rhythms under cyclopropane anesthesia. J. Pharmacol. exp. Ther. 94, 319–327 (1948)
Moore, R.M., Cannon, W.B.: The heart rate of unanaesthetised normal, vagotomised and sympathectomised cats as affected by atropine and ergotoxine. Amer. J. Physiol. 94, 201–208 (1930)
Moran, N.C., Perkins, M.E.: An evaluation of adrenergic blockade of the mammalian heart. J. Pharmacol. exp. Ther. 133, 192–201 (1961)
Morpugo, C., Faini, D., Falcone, A.: The effects of phentolamine, dihydroergocristine and isoxsuprine on the blood pressure and heart rate in normotensive, hypotensive and hypertensive rats. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 290, 335–346 (1975)
Mouillé, P.: Interactions entre divers inhibiteurs α et β adrenergiques et l’ergotamine au cours de l’inversion des effets trusionnels de l’isoprenaline chez le chien. C.R. Soc. Biol. (Paris) 164, 1003–1006 (1970)
Moyer, J.H., Handley, C.A., Seibert, R.A.: Effect of adrenergic blockade on renal hemodynamics and excretion of water and electrolytes. Amer. J. Physiol. 180, 146–150 (1955)
Mühe, E., Burhardt, K.-H., Kolb, W., Strobel, G.: Eine neue Methode zur Prophylaxie postoperativer Venenthrombosen. Klinikarzt 4, 88–92 (1975)
Müller-Schweinitzer, E.: Studies on the peripheral mode of action of dihydroergotamine in human and canine veins. Europ. J. Pharmacol. 27, 231–237 (1974)
Müller-Schweinitzer, E.: Responsiveness of isolated canine cerebral and peripheral arteries to ergotamine. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 292, 113–118 (1976)
Müller-Schweinitzer, E., Brundell, J.: Modification of canine vascular smooth muscle responses to dihydroergotamine by endogenous prostaglandin synthesis. Europ. J. Pharmacol. 34, 194–206 (1975a)
Müller-Schweinitzer, E., Brundell, J.: Enhanced prostaglandin synthesis contributes to the venoconstrictor activity of ergotamine. Blood Vessels 12, 193–205 (1975b)
Müller-Schweinitzer, E., Stürmer, E.: Investigations on the mode of action of ergotamine in the isolated femoral vein of the dog. Brit. J. Pharmacol. 51, 441–446 (1974)
Murphree, H.B., De Maar, E.W.J., Williams, H.L., Bryan, L.L.: Effects of lysergic acid derivatives on man; antagonism between d-lysergic acid diethylamide and its 2-brom congener. J. Pharmacol. exp. Ther. 122, 55A (1958)
Murray, R., Beck, L., Rondell, P.A., Bohr, D.F.: A study of the central action of ganglionic blocking agents. J. Pharmacol. exp. Ther. 127, 157–163 (1959)
Navratil, E.: Ueber humorale Uebertragbarkeit der Herznervenwirkung. Pflügers Arch. ges. Physiol. 217, 610–617 (1927)
Navratil, E., Wieninger, E.: Beitrag zur adrenolytischen Wirkung des Dihydroergotamins am Kaltblüterherz. Klin. Med. 3, 990–994 (1948)
Nickerson, M.: The pharmacology of adrenergic blockade. Pharmacol. Rev. 1, 27–101 (1949)
Nickerson, M., Chan, G.C.-M.: Blockade of responses of isolated myocardium to epinephrine. J. Pharmacol. exp. Ther. 133, 186–191 (1961)
Nickerson, M., Nomaguchi, G.M.: Mechanism of dibenamine protection against cyclopropaneepinephrine cardiac arrhythmias. J. Pharmacol. exp. Ther. 95, 1–11 (1949)
Nickerson, M., Nomaguchi, G.M.: Blockade of epinephrine-induced cardioacceleration in the frog. Amer. J. Physiol. 163, 484–504 (1950)
Nickerson, M., Henry, J.W., Nomaguchi, G.M.: Blockade of responses to epinephrine and norepinephrine by dibenamine congeners. J. Pharmacol. exp. Ther. 107, 300–309 (1953)
Niesel, P., Weigelin, E., Mohr, H.: Untersuchungen über die Wirkung von Hydergin und DHE 45 am intrakraniellen Kreislauf beim “Cold-Pressor-Test”. Klin. Wschr. 31, 948 (1953)
Nilsson, A., Hökfelt, B.: Effect of bromocriptine on blood pressure, plasma and urinary catecholamines and plasma renin activity (PRA) in patients with acromegaly. Acta endocr. (Kbh.) Suppl. 212, 95 (1977)
Nimmerfall, F., Rosenthaler, J.: Ergot alkaloids: Hepatic distribution and estimation of absorption by measurement of total radioactivity in bile and urine. J. Pharmacokinet. Biopharm. 4, 57–66 (1976)
Nishi, K.: The action of 5-hydroxytryptamine on chemoreceptor discharges of the cat’s carotid body. Brit. J. Pharmacol. 55, 27–40 (1975)
Nordenfelt, I., Mellander, S.: Central haemodynamic effects of dihydroergotamine in patients with orthostatic hypotension. Acta med. scand. 191, 115–120 (1972)
Norris, J.W., Hachinski, V.C., Cooper, P.W.: Changes in cerebral blood flow during a migraine attack. Brit. med. J. 3, 676–677 (1975)
Nueten, J.M. van: Comparative bioassay of vasoactive drugs using isolated perfused rabbit arteries. Europ. J. Pharmacol. 6, 286–293 (1969)
O’Brien, G.S., Murphy, Q.R., Meek, W.J.: The effect of sympathomimetic amines on arterial plasma potassium and cardiac rhythm in anaesthetised dogs. J. Pharmacol. exp. Ther. 109, 453–460 (1953)
Olesen, J.: Prostaglandin action on cerebral vessels. Headache 1976. Meeting of Ital. and Scand. Migraine Socs., Florence, June 2–3, 1976, p. 27
Olesen, J., Paulson, O.B., Lassen, N.A.: Regional cerebral blood flow in man determined by the initial slope of the clearance of intra-arterially injected 133Xe. Stroke 2, 519–539 (1971)
Olivecrona, H.: Notes on the surgical treatment of migraine. Acta med. scand. Suppl. 196, 229–238 (1947)
Orth, O.S.: The use of dihydroergotamine (DHE 45) and dihydroergocornine (DHO 180) to prevent cardiac irregularities during cycloproprane anaesthesia. Arch. int. Pharmacodyn. 78, 163–173 (1949)
Orth, S., Ritchie, G.: A pharmacological evaluation of dihydroergotamine methanesulphonate (DHE-45). J. Pharmacol. exp. Ther. 90, 166–173 (1947)
Osswald, W., Guimarães, S., Garrett, J.: Influence of propranolol and ICI 50,172 on the cardiovascular actions of catecholamines as modified by ergotamine. J. Pharmacol. exp. Ther. 174, 315–322 (1970)
Ostfeld, A.M.: Some aspects of cardiovascular regulation in man. Angiology 10, 34–42 (1959)
Ostfeld, A.M.: Migraine headache. Its physiology and biochemistry. J. Amer. med. Ass. 174, 1188–1190 (1960)
Ostfeld, A.M., Wolff, H.G.: Studies on headache observations on the behaviour of the conjunctival vessels in vascular headache. Trans. Amer. neurol. Ass. 80, 216–219 (1955)
Ostfeld, A.M., Chapman, L.F., Goodell, H., Wolff, H.G.: Studies in headache: Summary of evidence concerning a noxious agent active locally during migraine headache. Psychosom. Med. 19, 199–208 (1957)
Otto, H.L.: Upon the action of ergotoxin in the mammalian heart. J. Pharmacol. exp. Ther. 33, 285–293 (1928)
Owen, D.A.A., Stürmer, E.: Effect of dihydroergotamine (DHE) on the capacitance, resistance and precapillary sphincter vessels of denervated cat skeletal muscle. Brit. J. Pharmacol. 42, 655P–656P (1971)
Owen, D.A.A., Stürmer, E.: The effects of ergotamine and dihydroergotamine on skin and skeletal muscle vasculature. Experientia (Basel) 28, 743 (1972a)
Owen, D.A.A., Stürmer, E.: The effects of Hydergine on acutely denervated cat skeletal muscle vasculature. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 272, 395–401 (1972b)
Oyen, I.H.: Mechanism of early and chronic experimental renal hypertension as tested by CCK-179. Amer. J. Physiol. 186, 161–166 (1956)
Page, I.H., McCubbin, J.W.: Modification of vascular response to serotonin by drugs. Amer. J. Physiol. 174, 436–444 (1953)
Papp, J.G., Szekeres, L.: The arrhythmogenic action of sympathomimetic amines. Europ. J. Pharmacol. 3, 4–14 (1968)
Parade, D., Schwarz, W., Kroenig, B., Brocke, B., Jahnecke, J.: Durch Antihypertensiva hervorgerufener orthostatischer Blutdruckabfall und seine medikamentöse Beeinflussbarkeit. Med. Welt 25, 179–182 (1974)
Pattani, F.: Die Kreislaufwirkung der Dihydroderivate der genuinen Mutterkornalkaloide am kreislaufgesunden Menschen. Schwarzenburg: Gerber-Buchdruck 1949 (Diss.)
Peiss, C.N.: Concepts of cardiovascular regulation: past, present and future. In: Nervous control of the heart. Randall, W.C. (ed.), pp. 154–197. Baltimore: Williams and Wilkins Co. 1965
Pelofsky, S., Jacobson, E.D., Fischer, R.G.: Effects of prostaglandin Ei on experimental cerebral vasospasm. J. Neurosurg. 36, 634–639 (1972)
Penfield, W.: Operative treatment of migraine and observations on the mechanism of vascular pain. Trans. Amer. Acad. Ophthal. Otolaryng. 37, 50–64 (1932)
Pichler, E., Ostfeld, A.M., Goodell, H., Wolff, H.G.: Central versus peripheral action of ergotamine tartrate and its relevance to the therapy of migraine headache. Arch. Neurol. Psychiat. (Chic.) 76, 571–577 (1956)
Pickering, G.W.: Observations on the mechanism of headache produced by histamine. Clin. Sci. 1, 77–101 (1933)
Pool, J.L., Nason, G.J.: Comparative effects of ergotamine tartrate on the arteries of the pia, dura and skin of cats. Arch. Neurol. Psychiat. (Chic.) 33, 276–282 (1935)
Pool, J.L., Storch, T.J.C., Lennox, W.G.: Effect of ergotamine tartrate on pressure of cerebrospinal fluid and blood during migraine headache. Arch. int. Med. 57, 32–45 (1936)
Prochnik, G., Maison, G.L., Stutzman, J.W.: Carotid-occlusion-pressor reflex: influence of existing mean arterial pressure, of anaesthetics and of ganglionic-and adrenergic-blocking drugs. Amer. J. Physiol. 162, 553–559 (1950)
Proosdij-Hartzema, E.G. van, De Jongh, D.K.: Investigations into experimental hypotension. III. Dosage and effect of drugs in experimental renal hypertension in the rat. Acta physiol. Pharmacol. néerl. 4, 160–174 (1955)
Puglionisi, A., Eppinger, S.: L’azione dell’Hydergina sulla circolazione degli arti normali e nelle arteriopatie obliteranti periferiche croniche. Minerva chir. 8, 61 (1953)
Rand, M.J., Story, D.F., McCulloch, M.W.: Inhibitory feedback modulation of adrenergic transmission. Clin. exp. Pharmacol. physiol., Suppl. 2, 21–26 (1975)
Ray, B.S., Wolff, H.G.: Experimental studies on headache. Painsensitive structures of the head and their significance in headache. Arch. Surg. 41, 813–856 (1940)
Reckel, K.: Zur Behandlung pharmakogen bedingter orthostatischer Kreislaufdysregulationen. Ther. d. Gegenw. 109, 694–704 (1970)
Regli, F., Yamaguchi, T., Waltz, A.G.: Effects of vasodilating drugs on blood flow and the microvasculature of ischaemic and nonischaemic cerebral cortex. Arch. Neurol. (Chic.) 24, 467–474 (1971)
Rettori, O., Haley, T.J.: Peripheral versus central sites of action of ergotamine on blood flow. Arch. int. Pharmacodyn. 167, 473–478 (1967)
Reubi, F.: L’action de quelques dérivés de l’ergot de seigle sur la circulation rénale. Experientia (Basel) 5, 296–297 (1949)
Reubi, F.: Le flux sanguin rénal. Helv. med. Acta 17, Suppl. XXVI, Fasc. 2 (1950)
Reubi, F.: L’Hydergine modifie-t-elle l’activité tubulaire rénale? Helv. med. Acta 19, 1–8 (1952a)
Reubi, F.: Les fonctions rénales des hypertendus au cours d’un traitement prolongé par les dérivés dihydrogénés de l’ergot de seigle (Hydergine). Helv. med. Acta 19, 29–41 (1952b)
Rieckert, H.: Primäre Therapieziele bei der hypotonen Fehlregulation. Fortschr. Med. 89, 175–176 (1971)
Rieckert, H., Pauschinger, P.: Die Beeinflussung des peripheren Venentonus durch Dihydergotê. Arztl. Forsch. 21, 99–101 (1967)
Riley, H.A.: Migraine. Bull. neurol. Inst. N.Y. 2, 429–544 (1932)
Ripa, R., Frangipane, G., Gilli, P., Tura, S.: Azione della diidroergotamina sulla pressione arteriosa di ratta con ipertensione renale cronica. Boll. Soc. ital. Biol. sper. 43, 883–887 (1967)
Rosenblueth, A., Cannon, B.: Some circulatory phenomena disclosed by ergotoxine. Amer. J. Physiol. 105, 373–382 (1933)
Rosmanitz, I.J., Brehm, H.: Klinisch-experimentelle Studie zur Kreislaufwirkung des Dihydergot beim Orthostasesyndrom. Med. Welt 2, 2618–2625 (1964)
Rothlin, E.: Recherche experimentales sur l’ergotamine, alcaloïde spécifique de l’ergot de seigle. Arch. int. Pharmacodyn. 27, 459–479 (1923)
Rothlin, E.: Ueber die pharmakologische und therapeutische Wirkung des Ergotamins auf den Sympathikus. Klin. Wschr. 4, 1437–1443 (1925)
Rothlin, E.: Zur Pharmakologie der hydrierten naturlichen Mutterkornalkaloide Helv. physiol. Pharmacol. Acta 2, C48–C49 (1944)
Rothlin, E.: Ueber die adrenergischen Funktionen am Herz und an Gefässen. Bull. schweiz. Akad. med. Wiss. 1, 194–207 (1945)
Rothlin, E.: The pharmacology of the natural and dihydrogenated alkaloids of ergot. Bull. schweiz. Akad. med. Wiss. 2, 249–273 (1946)
Rothlin, E.: Zur Analyse der Blutdruckwirkung der natürlichen und dihydrierten Mutterkornalkaloide. Experientia (Basel) 5, 78–79 (1949)
Rothlin, E.: Pharmacology of lysergic acid diethylamide and some of its related compounds. J. Pharm. Pharmacol. 9, 569–587 (1957)
Rothlin, E., Cerletti, A.: Untersuchungen iiber die Kreislaufwirkung des Ergotamins. Helv. physiol. pharmacol. Acta 7, 333–370 (1949a)
Rothlin, E., Cerletti, A.: Pharmakologie des Hochdrucks. Verh. dtsch. Ges. Kreisl.-Forsch. 15, 158–185 (1949b)
Rothlin, E., Cerletti, A.: Ueber die Schutzwirkung von Hydergin gegen heterotope Reizbildungsstörungen. Cardiologia 15, 184–185 (1949c)
Rothlin, E., Cerletti, A.: Experimented Untersuchungen iiber die cardiale Wirkung hydrierter Mutterkornalkaloide. Z. ges. exp. Med. 122, 335–345 (1953)
Rothlin, E., Cerletti, A., Emmeneger, H.: Experimental psychoneurogenic hypertension and its treatment with hydrogenated ergot alkaloids (Hydergine). Acta med. scand., Suppl. 312, 27–35 (1956)
Rothman, S., Drury, D.R.: Role of autonomic nervous system in maintainance of cerebral and renal hypertension. Amer. J. Physiol. 188, 371–374 (1957)
Rowbotham, G.F.: Long term results of injuries of head (medical, economical and sociological survey). J. ment. Sci. 95, 336–354 (1949)
Sagar, S., Stamatakis, J.D., Higgins, A.F., Nairn, D., Maffei, F.H., Thomas, D.P., Kakkar, V.V.: Efficacy of low-dose heparin in prevention of extensive deep-vein thrombosis in patients undergoing total-hip replacement. Lancet I, 1151–1154 (1976)
Salmoiraghi, G.C., McCubbin, J.W., Page, I.H.: Effects of d-lysergic acid diethylamide and its brom derivative on cardiovascular responses to serotonin and on arterial pressure. J. Pharmacol. exp. Ther. 119, 240–247 (1957)
Salzmann, R., Pacha, W., Taeschler, M., Weidmann, H.: The effect of ergotamine on humoral and neuronal actions in the nictitating membrane and the spleen of the cat. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 261, 360–378 (1968)
Sankar, D.V. Siva: LSD — a total study. Westbury, N.Y.: PJD Publications Ltd. 1975
Saxena, P.R.: The effects of antimigraine drugs on the vascular responses by 5-hydroxytryptamine and related biogenic substances on the external carotid bed of dogs; possible pharmacological implications to their antimigraine action. Headache 12, 44–54 (1972)
Saxena, P.R.: Selective vasoconstriction in carotid vascular bed by methysergide: possible relevance to its antimigraine effect. Europ. J. Pharmacol. 27, 99–105 (1974)
Saxena, P.R., Bhargava, K.P.: The importance of a central adrenergic mechanism in the cardiovascular responses to ouabain. Europ. J. Pharmacol. 31, 332–346 (1975)
Saxena, P.R., Vlaam-Schluter, G.M. de: Role of some biogenic substances in migraine and relevant mechanisms in antimigraine action of ergotamine — studies in an experimental model for migraine. Headache 13, 142–163 (1974)
Schade, F.: Methergine: A study of its vasomotor properties. Amer. J. Obstet. Gynec. 61, 187–192 (1951)
Scheinberg, P.: Cerebral blood flow in vascular disease of the brain, with observations on the effect of stellate ganglion block. Amer. J. Med. 8, 139–147 (1950)
Schleimer, R., Zitowitz, L., Wohl, A.: The antiarrhythmic activity of dihydroergotamine (DHE). Pharmacologist 13, (2), 225 (1971)
Schlientz, W., Brunner, R., Rüegger, A., Berde, B., Stürmer, E., Hofmann, A.: β-Ergokryptin, ein neues Alkaloid der Ergotoxingruppe. Pharm. Acta Helv. 43, 497–509 (1968)
Schmidt, C.F.: The intrinsic regulation of the circulation in the hypothalamus of the cat. Amer. J. Physiol. 110, 137–152 (1934)
Schmitt, H.: Recherches sur le système nerveux sympathique. III Dissociation des effects des mediateurs chimiques de ceux de l’excitation des nerfs sympathiques. Arch. int. Pharmacodyn. 114, 381–396 (1958)
Schmitt, H., Fenard, S.: Effets des alcaloïdes de l’ergot de seigle sur les vasomoteurs et leur inhibition par la clonidine. C.R. Soc. Biol. (Paris) 164, 1006–1009 (1970)
Schmitt, H., Petillot, N.: Potentialisation des effets hypertenseurs de l’angiotensine par les alcaloides de l’ergot de seigle et par la vasopressine. C.R. Soc. Biol. (Paris) 163, 2551–2553 (1969)
Schmitt, H., Schmitt, H.: Action de l’ergotamine, de la hydroergotamine et de l’hydergine chez le lapin réserpiné. C.R. Soc. Biol. (Paris) 153, 748–749 (1959)
Schmitt, H., Schmitt, H.: Sur le méchanisme de l’action hypotensive de la dihydroergotamine. J. Physiol. (Paris) 52, 517–523 (1960)
Schmitt, H., Schmitt, H.:: Modifications de l’excitabilité des centres vasomoteurs par des substances interférant périphériquement avec les effets du systeme sympathique. Arch. int. Pharmacodyn. 150, 322–335 (1964)
Schmitt, H., Laubie, M., Fenard, S.: Effets hemodynamiques des alcaloides de l’ergot de seigle. J. Pharmacol. (Paris) 2, 131–140 (1971)
Schneider, M., Schneider, D.: Untersuchungen iiber die Regulierung der Gehirndurchblutung. II Einwirkung verschiedener Pharmaka auf die Gehirndurchblutung. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 175, 640–664 (1934)
Schneider, M., Wiemers, K.: Ueber die Wirkung der hydrierten Mutterkornalkaloide auf die Gehirndurchblutung. Klin. Wschr. 29, 580–581 (1951)
Scholtysik, G.: Inhibition of accelerator nerve stimulation in cats by dihydroergotoxine. 6th Int. Congr. Pharmacol. Helsinki, Finland, Abstr. 742 (1975)
Scholtysik, G.: Dopamine receptor mediated inhibition by bromocriptine of accelerator nerve stimulation effects in the pithed cat. Brit. J. Pharmacol. (1978) in press
Schön, H., Leist, K.H., Grauwiler, J.: Single day treatment of pregnant rats with ergotamine. Teratology 11, 32A (1975)
Schönbaum, E., Vargaftig, B.B., Lefort, J., Lamar, J.C., Haseneck, T.: An unexpected effect of serotonin antagonists on the canine nasal circulation. Headache 15, 180–187 (1975)
Share, N.N.: “Alpha” and “beta” adrenergic receptors in the medullary vasomotor centre of the cat. Arch. int. Pharmacodyn. 202, 362–373 (1973)
Shaw, E., Woolley, D.W.: Some serotonin-like activities of lysergic acid diethylamide. Science 124, 121–122 (1956)
Shen, T.C.R.: The protective action of piperido-methyl-3-benzodioxane (F-933), diethyl-aminomethyl-3-benzodioxane (F-883) and yohimbine upon the chloroform-adrenaline ventricular fibrillation. Arch. int. Pharmacodyn. 59, 243–251 (1938)
Sherif, M.A.F., Effat, S., Razzak, M.A.: Comparative study of some imidazoline derivatives and dihydrogenated ergot alkaloids on the cardiovascular system. Arch. int. Pharmacodyn. 108, 5–18 (1956)
Sicuteri, F.: L’acido vanilmandelico (VMA) il maggior metabolita urinario delle catecolamine. Sett. Med. 50, 227 (1962)
Sicuteri, F.: Mast cells and their active substances. Their role in the pathogenesis of migraine. Headache 3, 86–92 (1963)
Sicuteri, F., Ricci, M., Monfardini, R., Ficini, M.: Experimental headache with endogenous histamine. Acta allerg. (Kbh.) 11, 188–192 (1957)
Sicuteri, F., Testi, A., Anselmi, B.: Biochemical investigations in headache: increase in hydroxyindoleacetic acid excretion during migraine attacks. Int. Arch. Allergy 19, 55–58 (1961)
Sicuteri, F., Fanciullacci, M., Anselmi, B.: Bradykinin release and inactivation in man. Int. Arch. Allergy 22, 77–84 (1963)
Sicuteri, F., Franchi, G., Fanciullacci, M.: Serotonin potentiation of methysergide, LSD-25 and ergotamine in man: an informal approach to migraine pharmacology. In: Headache, 62 contributions to the present situation of headache research in the international and interdisciplinary view. II. Biochemical bases and drug therapy. Munch. Med. Wschr. (ed.), pp. 101–104. München 1975
Siggaard-Andersen, J., Bonde Petersen, F., Ulrich, J.: Treatment of arterial insufficiency in the lower limbs by Hydergin®. Angiology 22, 311–319 (1971)
Siggaard-Andersen, J., Petersen, F.B., Ulrich, J.: A double-blind cross-over examination studied by plethysmography. In: Gerontology. Proc. Vlth Congr. Clin. Gerontol., Berne, Sept. 8/11th, 1971, pp. 259–261. Bern: H. Huber 1973
Simard, D., Paulson, O.B.: Cerebral vasomotor paralysis during migraine attacks. Arch. Neurol. (Chic.) 29, 207–209 (1973)
Skinhøj, E.: Hemodynamic studies within the brain during migraine. Arch. Neurol. (Chic.) 29, 95–98 (1973)
Skinhøj, E., Paulson, O.B.: Regional blood flow in internal carotid distribution during migraine attack. Brit. med. J. 3, 569–570 (1969)
Sokoloff, L.: The actions of drugs on the cerebral circulation. Pharmacol. Rev. 11, 2–85 (1959)
Sokoloff, L., Perlin, S., Kornetsky, C., Kety, S.S.: Effects of lysergic acid diethylamide on cerebral circulation and metabolism in man. Fed. Proc. 15, 174 (1956)
Spira, P.J., Mylecharane, E.J., Lance, J.W.: The effects of humoral agents and antimigraine drugs on the cranial circulation of the monkey. Res. Clin. Stud. Headache 4, 37–75 (1976)
Spühler, O.: Dihydroergotamin (DHE) als Sympathicolyticum in der inneren Medizin. Schweiz. med. Wschr. 76, 1259–1263 (1946)
Starke, K.: Influence of aα-receptor stimulants on noradrenaline release. Naturwissenschaften 58, 420 (1971)
Starke, K.: Alpha sympathomimetic inhibition of adrenergic and cholinergic transmission in the rabbit heart. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 274, 18–45 (1972)
Starke, K.: Regulation of noradrenaline release by presynaptic receptor systems. Rev. Physiol. Biochem. Pharmacol. 77, 1–124 (1977)
Starke, K., Endo, T.: Presynaptic α-adrenoceptors. Gen. Pharmacol. 7, 307–312 (1976)
Starke, K., Montel, H., Wagner, J.: Effect of phentolamine on noradrenaline uptake and release. Naunyn-Schmiedebergs Arch. Pharmak. 271, 181–192 (1971)
Starke, K., Endo, T., Taube, H.D.: Relative pre-and postsynaptic potencies of α-adrenoceptor agonists in the rabbit pulmonary artery. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 291, 55–78 (1975a)
Starke, K., Borowski, E., Endo, T.: Preferential blockade of presynaptic α-adrenoceptors by yohimbine. Europ. J. Pharmacol. 34, 385–388 (1975b)
Steinmann, B., Lüdi, H., Barben, H.P.: Kreislaufuntersuchungen mit vegetativ dämpfenden Pharmaka. Helv. med. Acta 15, 1–19 (1948)
Stjärne, L.: Basic mechanisms and local feedback control of secretion of adrenergic and cholinergic neurotransmitters. In: Handbook of Psychopharmacology, Vol. 6. Iverson, L.L., Iverson, S.D., Snyder, S.H. (eds.), pp. 179–233. New York: Plenum Press 1975
Stjärne, L., Brundin, J.: Dual adrenoceptor-mediated control of noradrenaline secretion from human vasoconstrictor nerves. Facilitation by β-receptors and inhibition by α-receptors. Acta physiol. scand. 94, 139–141 (1975)
Ströder, U., Koppermann, E.: Der Einfluß hydrierter Mutterkornalkaloide auf das Steh-Ekg unter besonderer Berücksichtigung der Hämodynamik. Z. Kreisl.-Forsch. 41, 21–31 (1952)
Stumpe, K.O., Kolloch, R., Higuchi, M., Krück, F., Vetter, H.: Hyperprolactinaemia and antihypertensive effect of bromocriptine in essential hypertension. Lancet 2, 211–214 (1977)
Stürmer, E., Cerletti, A.: The effect of drugs on spontaneous and bradykinin-stimulated lymph flow in dogs. 3rd Int. Congr. Pharmacol. São Paulo, Brazil; Int. Symp. on Vaso-active polypeptides: Bradykinin and related kinins. Rocha e Silva, M., Rothschild, A. (eds.), pp. 74–80. Sao Paulo: Edart Livraria Editora Ltda. 1967
Stürmer, E.: The effect of Hydergine® on spontaneous and bradykinin-stimulated lymph flow in dogs. In: Progress in lymphology. Mayall, R.C., Witte, M.H. (eds.), pp. 47–54. Plenum Press 1977
Stutzman, J.W., Murphy, Q., Allen, C.R., Meek, W.J.: Further studies on the production of cyclopropane-epinephrine tachycardia. Anesthesiology 8, 579–583 (1947)
Sugaar, S., Fried, G.H., Kalberer, J., Antopol, W.: Effect of lysergic acid diethylamide and its brom analogue on arterial hypertension in the rat. Amer. J. Physiol. 201, 1131–1133 (1961)
Sutton, G.C., Cerletti, A., Taeschler, M.: Comparative analysis of the effect of hydrogenated ergot alkaloids upon presso-and chemoreceptive reflexes in the cat. Arch. int. Pharmacodyn. 84, 393–400 (1950)
Szewczykowski, J., Meyer, J.S., Kondo, A., Nomura, F., Teraura, T.: Effects of ergot alkaloids (Hydergine) on cerebral hemodynamics and oxygen consumption in monkeys. J. Neurol. Sci. 10, 25–31 (1970)
Tadepalli, A.S., Mills, E., Schanberg, S.M.: Depression and enhancement of baroreceptor pressor response in cats after intracerebroventricular injection of noradrenergic blocking agents. Circulat. Res. 39, 724–730 (1976)
Taeschler, M.: Pharmacologic classique de l’Hydergine. Ann. Anesth. Franç. 6, spécial 2, 97–104 (1965)
Taeschler, M., Cerletti, A., Rothlin, E.: Zur Frage der Hyderginwirkung auf die Gehirnzirkulation. Helv. physiol. pharmacol. Acta 10, 120–137 (1952)
Tauberger, G. von, Klimmer, O.R.: Die Wirkungen hoher Dosen von d-Lysergsäurediäthylamid auf die Atmung, den Kreislauf und den zentralen Sympathicus-Tonus der Katze. Arzneimittel-Forsch. 18, 1489–1491 (1968)
Teychenne, P.F., Calne, D.B., Leigh, P.N., Greenacre, J.K., Reid, J.L., Petrie, A., Bamji, A.N.: Idiopathic parkinsonism treated with bromocriptine. Lancet 3, 473–476 (1975)
Thomson, W.H.: Ergot in the treatment of periodic neuralgias. J. nerv. ment. Dis. 19, 124–125 (1894)
Thorner, M.O., Chait, A., Aitken, M., Benker, G., Bloom, S.R., Mortimer, C.H., Sanders, P., Mason, A.S., Besser, G.M.: Bromocriptine treatment of acromegaly. Brit. med. J. 1, 299–303 (1975)
Tillgren, N.: Huvudvärksundersökningar med dihydroergotamintartrat. Huvudvärk och kärlens kontraktionstillständ. (Kopfschmerzuntersuchungen mit DHE. Kopfschmerz-und Kontraktionszustand der Gefäße.) Nord. Med. 33, 502 (1947)
Trautmann, E.: Die Beeinflussung migräneartiger Zustände durch ein sympathikushemmendes Mittel (Gynergen). Munch. med. Wschr. 75, 513 (1928)
Tronnier, H.: Gefäßwirksame Kosmetika. J. Soc. Cosmet. Chemists 21, 299–311 (1970)
Tunis, M.M., Wolff, H.G.: Analysis of cranial artery pulse waves in patients with vascular headache of the migraine type. Amer. J. med. Sci. 224, 565–568 (1962)
Tzanck, A.: Le traitement des migraines par le tartrate d’ergotamine. Bull. Soc. Med. Paris 44, 1057 (1928)
Ulrich, J., Siggaard-Andersen, J.: Vascular effects of dihydrogenated ergot alkaloids. Angiology 22,622–628 (1971)
Ulrich, J., Jessen, B., Siggaard-Andersen, J.: Comparative effects of dihydroergotamine and Hydergin® on the blood flow, capillary filtration rate and the capacitance vessels in the human calf studied by plethysmography. Angiology 24, 657–663 (1973)
Uvnäs, B.: Cholinergic muscle vasodilation. In: Cardiovascular regulation in health and disease. Bartorelli, C., Zanchetti, A. (eds.), pp. 7–32. Milan: Grafiche Elli and Pagani 1971
Vargaftig, B.B., Lefort, J.: Pharmacological evidence for a vasodilator receptor to serotonin in the nasal vessels of the dog. Europ. J. Pharmacol. 25, 216–225 (1974)
Vleeschhouwer, G.R. de: On the pharmacology of dihydroergotamine. Arch. int. Pharmacodyn. 78, 461–473 (1949)
Volkman, P.H., Goldberg, L.I.: Lack of correlation between inhibition of prolactin release and stimulation of dopaminergic renal vasodilation. Pharmacologist 18, 130 (1976)
Walker, R.J., Woodruff, G.N., Glaizner, B., Sedden, C.B., Kerkut, G.A.: The pharmacology of Helix dopamine receptor of specific neurones in the snail, Helix aspersa. Comp. Biochem. Physiol. 24, 455–469 (1968)
Weidmann, H., Cerletti, A.: Weiterer Beitrag zur Pharmakologie von d-Lysergsäure-diäthylamid: Die Wirkung von LSD auf Kreislaufreflexe. Helv. physiol. pharmacol. Acta 16, C38–C40 (1958)
Weidmann, H., Taeschler, M.: Influence des substances antimigraineuses sur les effets des catecholamines, de la sérotonin et de la stimulation des nerfs sympathiques. Symp. sur les cephalees vasculaires, 15–16 October, St-Germain-en-Laye. Sandoz editions, pp. 33–40, 1966
Weil, M.H., Shubin, H.: Changes in venous capacitance during cardiogenic shock — a search for the third dimension. Amer. J. Cardiol. 26, 613–614 (1970)
Welch, K.M.A., Knowles, L., Spira, P.: Local effect of prostalandins on cat pial arteries. Europ. J. Pharmacol. 25, 155–158 (1974a)
Welch, K.M.A., Spira, P.J., Knowles, L., Lance, J.W.: Simultaneous measurement of internal and external carotid blood flow in the monkey. An approach to the study of migraine mechanisms. Neurology (Minneap.) 24, 450–457 (1974b)
Wellens, D., Wauters, E.: Norepinephrine-induced reflex vasodilation and adrenergic betareceptors. Arch. int. Pharmacodyn. 159, 401–406 (1966a)
Wellens, D., Wauters, E.: Norepinephrine-induced reflex vasodilation and vascular effects of serotonin. Arch. int. Pharmacodyn. 164, 140–149 (1966b)
Wellens, D., Wauters, E.: Modification of the haemodynamic effects of isoproterenol by ergotamine. Arch. int. Pharmacodyn. 171, 246–250 (1968)
Welsh, J.H.: Excitation of the heart of venous mercenaria. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 219, 23–29 (1953)
Welsh, J.H.: Serotonin as a possible neurohumoral agent: evidence obtained in lower animals. Ann. N. Y. Acad. Sci. 66, 618–630 (1957)
Welsh, J.H., McCoy, A.C.: Actions of d-lysergic acid diethylamide and its 2-bromo derivative on heart of venus mercenaria. Science 125, 348 (1957)
Welsh, J.H., Moorhead, M.: Identification and assay of 5-hydroxytryptamine in molluscan tissues by fluorescence method. Science 129, 1491–1492 (1959)
Welsh, J.H., Moorhead, M.: The quantitative distribution of 5-hydroxytryptamine in the invertebrates, especially in their nervous systems. J. Neurochem. 6, 146–169 (1960)
Wenzel, D.G., Su, J.L.: Interactions between sympathomimetic amines and blocking agents on the rat ventricle strip. Arch. int. Pharmacodyn. 160, 379–389 (1966)
Wenzel, D.G., Ingianna, J., Grundeman, B.E.: Vascular interaction of ergonovine with nicotine or epinephrine in the rat tail. Arch. int. Pharmacodyn. 150, 186–190 (1964)
Werkö, L., Lagerlöf, H.: The effect of dihydroergotamine and dihydroergocornine on cardiac output and blood pressure in hypertension. Cardiologia 15, 120–126 (1949)
Wezler, K., Boeger, A.: Die Dynamik des arteriellen Systems. Ergebn. Physiol. 41, 292–606 (1939)
White, J.C., Smithwick, R.H.: The autonomic nervous system, p. 255. London: Kimpton 1944
White, J.M. Jr., Noltensmeyer, M.H., Morris, L.E.: The influence of dihydroergotamine methanesulphonate (DHE-45) on epinephrine induced cardiac irregularities in dogs during anaesthesia with several agents. Arch. int. Pharmacodyn. 88, 361–367 (1951)
Wolff, H.G: Headache and other head pain. New York: Oxford University Press 1948
Wolff, H.G: Headache and other head pain, 2nd ed. New York: Oxford University Press 1963
Wolff, H.G: Headache and other head pain, 3rd ed., rev. by D.J. Dalessio. New York: Oxford University Press 1972
Wolff, H.G., Hardy, J.D., Goodell, H.: Measurement of the effect on the pain threshold of acetylsalicylic acid, acetanilid, acetophenetidin, aminopyrine, ethyl alcohol, trichlorethylene, a barbiturate, quinine, ergotamine tartrate and caffeine: an analysis of their relation to the pain experience. J. clin. Invest. 20, 63–80 (1941)
Woods, G.G., Nelson, V.E., Nelson, E.E.: The effect of small amounts of ergotamine on the circulatory response to epinephrine. J. Pharmacol. exp. Ther. 45, 403–418 (1932)
Wright, S.: Studies of reflex activity in involuntary nervous system. II Action of ergotamine on vasomotor reflexes. J. Physiol. (Lond.) 69, 331–348 (1930)
Wright, A.McC., Moorhead, M., Welsh, J.H.: Actions of derivatives of lysergic acid on the heart of venus mercenaria. Brit. J. Pharmacol. 18, 440–450 (1962)
Yeh, B.J., McNay, J.L., Goldberg, L.I.: Attenuation of dopamine renal and mesenteric vasodilation by haloperidol: evidence for a specific receptor. J. Pharmacol. exp. Ther. 168, 303–309 (1969)
Youmans, J.B., Trabue, C., Buvinger, R.S., Frank, H.: Experimental and clinical studies of ergotamine. V. The action of ergotamine on the sympathetic nervous system stimulated by epinephrine. Studies of the metabolic rate, pulse rate, blood pressure, blood sugar and the total leukocyte count. Ann. int. Med. 7, 653–663 (1933)
Zickgraf, H.: Die Wirkung der dihydrierten Mutterkornalkaloide auf den Kreislauf. Z. klin. Med. 145, 34–50 (1949)
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1978 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Clark, B.J., Chu, D., Aellig, W.H. (1978). Actions on the Heart and Circulation. In: Berde, B., Schild, H.O. (eds) Ergot Alkaloids and Related Compounds. Handbook of Experimental Pharmacology / Handbuch der experimentellen Pharmakologie, vol 49. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-66775-6_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-66775-6_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-66777-0
Online ISBN: 978-3-642-66775-6
eBook Packages: Springer Book Archive